Infectious diseases company Pneumagen (Holdings) Ltd on Wednesday announced GBP4m in investment led by Thairm Bio, Scottish Investment Bank (SIB) to progress the company's lead candidate, Neumifil into a clinical trial for COVID-19.
Neumifil is a first-in-class Carbohydrate Binding Modules (mCBMs), generated using Pneumagen's proprietary GlycoTarge platform. It is being developed for the universal treatment of respiratory tract infections (RTIs) caused by Influenza Virus and Respiratory Syncytial Virus and now coronaviruses including SARS-CoV-2, the cause of COVID-19.
The investment follows exciting data from Pneumagen's pre-clinical studies in COVID-19 using plaque reduction assays. The testing conducted at Public Health England's (PHE) Porton facility and from the University of Glasgow's MRC Centre for Virus Research, demonstrated efficacy in inhibiting SARS-CoV-2 infection.
(USD1=GBP0.82)
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients